Condition: Chronic Myeloid Leukemia · Sponsor: Peking University People's Hospital
This is a prospective multi-center study to investigate efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) combined with azacitidine and B-cell lymphoma-2 (Bcl-2) inhibitor in patients with myeloid blast phase chronic myeloid leukemia (CML-MBP).
This description comes directly from the study's public registry record.
Qian Jiang, MD · +861088326006 · jiangqian@medmail.com.cn
Always discuss trial participation with your own doctor first.
| Peking university people's hospital | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Lu Daopei Hospital | Beijing, China | Recruiting |
| Chuiyangliu hospital affiliated to tsinghua university | Beijing, China | Not Yet Recruiting |
| Sichuan Provincial People's Hospital | Chengdu, China | Not Yet Recruiting |
| Nanfang Hospital, Southern Medical University | Guangdong, China | Not Yet Recruiting |
| The First Affiliated Hospital of Kunming Medical University | Kunming, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing, China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, China | Recruiting |
| Nanyang Central Hospital | Nanyang, China | Recruiting |
| Ningbo Medical Center Lihuili Hospital | Ningbo, China | Recruiting |
| Qilu Hospital of Shandong University | Qilu, China | Not Yet Recruiting |
| Chinese Academy of Medical Sciences & Peking Union Medical College Hospital | Tianjin, China | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06390306